相似文献
1
[Prognosis for rheumatoid arthritis].
Versicherungsmedizin. 2015 Mar 1;67(1):36.
2
[Statement of the German Society of Rheumatology (DGRh) reporting on the Institute's plan for biologicals in the second-line therapy for rheumatoid arthritis].
Z Rheumatol. 2011 Dec;70(10):882-3. doi: 10.1007/s00393-011-0910-7.
3
The case against haste in the treatment of rheumatoid arthritis: comment on the editorial by Pincus et al.
Arthritis Rheum. 2003 Feb;48(2):573-5; author reply 576-9. doi: 10.1002/art.10742.
4
Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).
Rheumatology (Oxford). 2006 Jun;45(6):649-52. doi: 10.1093/rheumatology/kel053. Epub 2006 Mar 9.
5
Hotel-based rheumatology, and more.
J Rheumatol. 2009 Feb;36(2):455-6; author reply 456-7. doi: 10.3899/jrheum.080818.
6
Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis.
J Rheumatol. 2005 Jan;32(1):6-10.
7
Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
J Rheumatol. 2009 Aug;36(8):1561-2. doi: 10.3899/jrheum.090594.
8
Measures of rheumatoid arthritis disease activity.
J Rheumatol. 2009 Feb;36(2):442-3; author reply 443-4. doi: 10.3899/jrheum.080923.
9
[Implementation and use of biosimilars in the therapy of inflammatory rheumatic diseases: Statement of the German Society of Rheumatology].
Z Rheumatol. 2014 Nov;73(9):784-6. doi: 10.1007/s00393-014-1505-x.
10
Rheumatoid arthritis: 2011 remission criteria are a new benchmark for RA therapy.
Nat Rev Rheumatol. 2011 Jun;7(6):317-8. doi: 10.1038/nrrheum.2011.63. Epub 2011 May 10.
Zotero 插件